Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014 (2014), Article ID 803832, 8 pages
http://dx.doi.org/10.1155/2014/803832
Research Article

JTT-130, a Novel Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein, Improves Hyperglycemia and Dyslipidemia Independent of Suppression of Food Intake in Diabetic Rats

Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan

Received 17 March 2014; Accepted 13 April 2014; Published 7 May 2014

Academic Editor: Masami Shinohara

Copyright © 2014 Shohei Sakata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. K. L. Wyne, “The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy,” Diabetes, Obesity and Metabolism, vol. 8, no. 4, pp. 365–380, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. G. M. Reaven, “Role of insulin resistance in human disease,” Diabetes, vol. 37, no. 12, pp. 1595–1607, 1988. View at Google Scholar · View at Scopus
  4. I. Lemieux, A. Pascot, C. Couillard et al., “Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?” Circulation, vol. 102, no. 2, pp. 179–184, 2000. View at Google Scholar · View at Scopus
  5. Y. Xie, E. P. Newberry, S. G. Young et al., “Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency,” Journal of Biological Chemistry, vol. 281, no. 7, pp. 4075–4086, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Mera, N. Odani, T. Kawai et al., “Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4′-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein,” Journal of Pharmacology and Experimental Therapeutics, vol. 336, no. 2, pp. 321–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Hata, Y. Mera, Y. Ishii et al., “JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner,” Journal of Pharmacology and Experimental Therapeutics, vol. 336, no. 3, pp. 850–856, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Hata, Y. Mera, T. Kawai et al., “JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty rats,” Diabetes, Obesity and Metabolism, vol. 13, no. 7, pp. 629–638, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Hata, Y. Mera, H. Tadaki et al., “JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats,” Diabetes, Obesity and Metabolism, vol. 13, no. 5, pp. 446–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. R. H. Unger, “Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: Genetic and clinical implications,” Diabetes, vol. 44, no. 8, pp. 863–870, 1995. View at Google Scholar · View at Scopus
  11. J. Capeau, “Insulin resistance and steatosis in humans,” Diabetes & Metabolism, vol. 34, no. 6, pp. 649–657, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Virtue and A. Vidal-Puig, “Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome—an allostatic perspective,” Biochimica et Biophysica Acta, vol. 1801, no. 3, pp. 338–349, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Kirk, D. N. Reeds, B. N. Finck, M. S. Mayurranjan, B. W. Patterson, and S. Klein, “Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction,” Gastroenterology, vol. 136, no. 5, pp. 1552–1560, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. J. Drucker, “The role of gut hormones in glucose homeostasis,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 24–32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. He, H. Su, W. Gao et al., “Reversal of obesity and insulin resistance by a non- peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice,” PLoS ONE, vol. 5, no. 12, Article ID e14205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Sebokova, A. Bénardeau, U. Sprecher, S. Sewing, L. Tobalina, and C. Migliorini, “Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat,” Diabetes, Obesity and Metabolism, vol. 12, no. 8, pp. 674–682, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. A. Young, B. R. Gedulin, S. Bhavsar et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, vol. 48, no. 5, pp. 1026–1034, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. B. R. Gedulin, S. E. Nikoulina, P. A. Smith et al., “Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight,” Endocrinology, vol. 146, no. 4, pp. 2069–2076, 2005. View at Google Scholar · View at Scopus
  19. Y. S. Lee, M. S. Park, J. S. Choung et al., “Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes,” Diabetologia, vol. 55, no. 9, pp. 2456–2468, 2012. View at Google Scholar
  20. L. Farilla, H. Hongxiang, C. Bertolotto et al., “Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats,” Endocrinology, vol. 143, no. 11, pp. 4397–4408, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. G. B. Parsons, D. W. Souza, H. Wu et al., “Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes,” Gene Therapy, vol. 14, no. 1, pp. 38–48, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Lee, H. Hirose, M. Ohneda, J. H. Johnson, J. D. McGarry, and R. H. Unger, “β-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 23, pp. 10878–10882, 1994. View at Publisher · View at Google Scholar · View at Scopus